Prevalence of narcolepsy in two European countries - France and Germany

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/48037
• EU PAS number:
  EUPAS48036
• Study ID:
  48037
• Official title and acronym:
  Prevalence of narcolepsy in two European countries - France and Germany
• DARWIN EU® study:
  No
• Study countries:
  France

  Germany
• Study description:
  The prevalence of narcolepsy in Europe is unclear at the moment due to contradictory studies and to the impact of the H1N1 vaccination on the overall prevalence. An updated prevalence for this condition is required for regulatory purposes. The main objective of this study was to provide the yearly prevalence of narcolepsy in France and Germany primary care settings, between 2011 and 2019. The yearly prevalence was stratified by sex and age group.
• Study status:
  Finalised

Research institution and networks

Institutions

European Medicines Agency (EMA)

Study timelines

Date when funding contract was signed

Planned: 15/10/2021

Actual: 15/10/2021

Study start date

Planned: 15/10/2021

Actual: 15/10/2021

Date of final study report

Planned: 25/10/2021

Actual: 25/10/2021

Sources of funding

EMA

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable